Literature DB >> 28942358

Claspin functions in cell homeostasis-A link to cancer?

Diana Azenha1, Maria Celeste Lopes2, Teresa C Martins3.   

Abstract

Cancer remains one of the leading causes of mortality worldwide. Most cancers present high degrees of genomic instability. DNA damage and replication checkpoints function as barriers to halt cell cycle progression until damage is resolved, preventing the perpetuation of errors. Activation of these checkpoints is critically dependent on Claspin, an adaptor protein that mediates the phosphorylation of the effector kinase Chk1 by ATR. However, Claspin also performs other roles related to the protection and maintenance of cell and genome integrity. For instance, following DNA damage and checkpoint activation, Claspin bridges checkpoint responses to DNA repair or to apoptosis. During DNA replication, Claspin acts a sensor and couples DNA unwinding to strand polymerization, and may also indirectly regulate replication initiation at firing origins. As Claspin participates in several processes that are vital to maintenance of cell homeostasis, its function is tightly regulated at multiple levels. Nevertheless, little is known about its role in cancer. Accumulating evidence suggests that Claspin inactivation could be an essential event during carcinogenesis, indicating that Claspin may function as a tumour suppressor. In this review, we will examine the functions of Claspin and how its deregulation may contribute to cancer initiation and progression. To conclude, we will discuss means by which Claspin can be targeted for cancer therapy.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Cell cycle checkpoints; Claspin; Genomic instability

Mesh:

Substances:

Year:  2017        PMID: 28942358     DOI: 10.1016/j.dnarep.2017.09.002

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  7 in total

1.  Exome sequencing in 51 early onset non-familial CRC cases.

Authors:  Jessada Thutkawkorapin; Annika Lindblom; Emma Tham
Journal:  Mol Genet Genomic Med       Date:  2019-02-27       Impact factor: 2.183

Review 2.  Involvement of E3 Ligases and Deubiquitinases in the Control of HIF-α Subunit Abundance.

Authors:  Kateryna Kubaichuk; Thomas Kietzmann
Journal:  Cells       Date:  2019-06-15       Impact factor: 6.600

3.  Claspin overexpression is associated with high-grade histology and poor prognosis in renal cell carcinoma.

Authors:  Go Kobayashi; Kazuhiro Sentani; Takashi Babasaki; Yohei Sekino; Yoshinori Shigematsu; Tetsutaro Hayashi; Naohide Oue; Jun Teishima; Akio Matsubara; Naomi Sasaki; Wataru Yasui
Journal:  Cancer Sci       Date:  2020-02-03       Impact factor: 6.716

4.  The Swr1 chromatin-remodeling complex prevents genome instability induced by replication fork progression defects.

Authors:  Anjana Srivatsan; Bin-Zhong Li; Barnabas Szakal; Dana Branzei; Christopher D Putnam; Richard D Kolodner
Journal:  Nat Commun       Date:  2018-09-11       Impact factor: 14.919

5.  Alpha-lipoic acid alters the antitumor effect of bortezomib in melanoma cells in vitro.

Authors:  Angéla Takács; Eszter Lajkó; Orsolya Láng; Ildikó Istenes; László Kőhidai
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

6.  Antiproliferative chromone derivatives induce K562 cell death through endogenous and exogenous pathways.

Authors:  Runwei Jiao; Fanxing Xu; Xiaofang Huang; Haonan Li; Weiwei Liu; Hao Cao; Linghe Zang; Zhanlin Li; Huiming Hua; Dahong Li
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

7.  HAS3-induced extracellular vesicles from melanoma cells stimulate IHH mediated c-Myc upregulation via the hedgehog signaling pathway in target cells.

Authors:  Uma Thanigai Arasu; Ashik Jawahar Deen; Sanna Pasonen-Seppänen; Sami Heikkinen; Maciej Lalowski; Riikka Kärnä; Kai Härkönen; Petri Mäkinen; Elisa Lázaro-Ibáñez; Pia R-M Siljander; Sanna Oikari; Anna-Liisa Levonen; Kirsi Rilla
Journal:  Cell Mol Life Sci       Date:  2019-12-09       Impact factor: 9.261

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.